Checking the Effectiveness of Two Medicines for Advanced Lung Cancer Treatment
NCT05211895 · RecruitingThis trial is looking at how well two medicines, durvalumab and domvanalimab, work together after patients receive certain types of radiation and chemotherapy. It focuses on adults with locally advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed. The main goal is to check how effective and safe this combination is for keeping the cancer under control.
Locations and contact
This trial is running at 264 locations. The first 8 are listed here.
- Research SiteChandler, ArizonaRecruiting
- Research SitePhoenix, ArizonaSuspended
- Research SiteFountain Valley, CaliforniaRecruiting
- Research SiteSanta Rosa, CaliforniaRecruiting
- Research SiteWashington D.C., District of ColumbiaRecruiting
- Research SiteJacksonville, FloridaSuspended
- Research SiteOrlando, FloridaRecruiting
- Research SiteSaint Augustine, FloridaRecruiting
Who can join
Adults aged 18 and older can join this study. It is open to men and women who have been treated for Stage III NSCLC and have not seen their cancer progress after treatment. The trial team will confirm if you meet all the requirements.
What happens during the trial
Participants will be randomly assigned to one of two groups. One group will receive durvalumab and domvanalimab together, while the other group will get durvalumab with a placebo (a treatment that looks like the real medicine but has no active ingredients). Everyone will receive their treatment through an IV infusion every four weeks for up to a year.
The trial team
The trial is sponsored by AstraZeneca, and they are working with Arcus Biosciences, Inc. The lead doctors are Hidehito Horinouchi from the National Cancer Center Hospital, Alexander Spira from Virginia Cancer Specialists Research Institute, and Jinming Yu from Shandong Cancer Hospital and Institute.
Important dates
The trial started on February 18, 2022, and is currently recruiting participants. It is expected to finish by October 1, 2030.
Additional information
The trial's ID number is NCT05211895. It is a Phase 3 study, which means the trial is testing how well the treatment works and how safe it is. The trial is FDA-regulated and plans to include about 860 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →